Compare Adaptive Biotechnologies Corp (ADPT) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Salesforce Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Salesforce Inc trades at $166.48 (market cap $138.84B). The key difference: Salesforce Inc is far larger — about 41.7× Adaptive Biotechnologies Corp's market cap, and Salesforce Inc pays a 1.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CRM | |
|---|---|---|
Market Cap | $3.33B | $138.84B |
Sector | Health | Technology |
52-Week High | $22.37 | $273.65 |
52-Week Low | $10.24 | $150.12 |
Enterprise Value | $3.19B | $168.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Salesforce (CRM) trades at $166.00, up 0.21% on the day, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 19.64, revenue of $37.90 billion for 2025, and net income of $6.20 billion, supported by consistent earnings beats. Recent news highlights AI momentum and a significant year-to-date decline, with analyst consensus remaining strongly positive.
Outlook is favorable due to robust profitability, AI integration, and a consensus price target of $235.20, implying over 40% upside. Risks include market volatility, competitive pressures in SaaS, and macroeconomic headwinds affecting tech stocks, but strong cash flow and institutional support provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
